Farletuzumab
FR-alpha | |
|---|---|
| Clinical data | |
| Routes of administration | Intravenous injection |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6466H9928N1716O2020S42 |
| Molar mass | 145371.06 g·mol−1 |
  (what is this?) (verify) | |
Farletuzumab (MORAb-003) is a humanized
monoclonal antibody[1] of IgG1/κ[2] which is being investigated for the treatment of ovarian cancer.[3][4]
This drug was developed by Morphotek, Inc.
It is targeted at
non-small-cell lung carcinoma.[2]
Mechanism of action
Farletuzumab uses the following mechanisms of action:[2]
- Antibody-dependent cellular cytotoxicity
- Complement-dependent cytotoxicity
- Inhibition of interaction between FRα and Lyn kinase
- Induces cell death associated with autophagy
Adverse effects
Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.[2]
References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
- ^ PMID 27022278.
- ^ Clinical trial number NCT00738699 for "Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT00849667 for "Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |